Cecilia Gonzalo in a managing director of Vatera Holdings. In addition to being a member of the Board of Directors of Melinta Therapeutics, she is a member of the Board of Directors of Edgemont Pharmaceuticals, LLC and Ekteino Laboratories, Inc. Ms. Gonzalo also previously served on the Board of Directors of Allos Therapeutics, Inc., Bausch & Lomb Incorporated (observer), Eurand N.V, LaVie Care Centers, Prestwick Pharmaceuticals, Inc., and Talon Therapeutics, Inc., among others.
Prior to joining Vatera, Cecilia was a managing director at Essex Woodlands, a healthcare focused growth equity firm where she worked on investing across the healthcare sector in the US, Latin America and Europe. Before Essex Woodlands, Cecilia spent twelve years at Warburg Pincus where she was a managing director focusing on healthcare investments. Before Warburg Pincus, she was an analyst at Goldman Sachs, first in Investment Banking and then in the Principal Investment Area. Cecilia earned her Bachelor of Arts degree in Biochemical Sciences from Harvard College and her Master of Business Administration from Harvard Business School. She is currently a board member and the treasurer of the Harvard Business School Healthcare Alumni Association. Cecilia is fluent in Spanish, Portuguese, and French.